Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.93 USD | -0.56% | -1.75% | -17.38% |
Apr. 17 | UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating | MT |
Apr. 15 | Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.38% | 83.46B | |
+28.79% | 676B | |
+24.95% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+3.34% | 210B | |
-0.13% | 204B | |
-9.65% | 194B | |
-11.71% | 144B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Market Chatter: US Appeals Court Overturns $1.2 Billion Verdict Against Gilead Sciences, Invalidates Bristol Myers CAR-T Patent